Tuesday, March 27, 2018 9:05:15 AM
You are right. I expected more too. Unfortunately.
We have to think what they should do now. My opinion is, they should combine Focalin and PODRAS. Maybe Seroquel and PODRAS too.
What I mean, they should make two new products taking two old and already marketed products and combine them with PODRAS.
This would be best way to make PODRAS technology accepted by FDA. This would give several benefits. First neither of these products would have direct competition, because there would not be anything like them marketed before. Second issue is, they can set them different price. Not the same present products without PODRAS have. Third and most important is, this would be easiest way to have PODRAS technology accepted by FDA. All they have to do is proving the drugs with or without PODRAS have same effect, but the other one has overdose prevention.
And yes - I have sent the same thoughts to Odidis, Patient and Akyempon too. I just hope they have enough cash to make new products Focalin PODRAS and Seroquel PODRAS.
I very much doubt MNK would not be the best partner to sell Seroquel PODRAS. Maybe they can find an other.
Recent IPCI News
- Suspension de la négociation par l'Organisme canadien de réglementation des investissements - IPCI • PR Newswire (Canada) • 03/06/2024 12:55:00 PM
- Canadian Investment Regulatory Organization Trading Halt - IPCI • PR Newswire (Canada) • 03/06/2024 12:51:00 PM
- L'Organisme canadien de réglementation des investissements permet la reprise de la négociation - IPCI • PR Newswire (Canada) • 06/08/2023 05:30:00 PM
- Canadian Investment Regulatory Organization Trade Resumption - IPCI • PR Newswire (Canada) • 06/08/2023 05:28:00 PM
- Intellipharmaceutics Announces Fiscal Year 2022 and First Quarter 2023 Results • PR Newswire (Canada) • 06/06/2023 10:00:00 AM
FEATURED Music Licensing, Inc. (OTC: SONG) Subsidiary Pro Music Rights Secures Final Judgment of $114,081.30 USD, Demonstrating Strength of Licensing Agreements • May 17, 2024 11:00 AM
Greenlite Ventures Inks Deal to Acquire No Limit Technology • GRNL • May 17, 2024 3:00 PM
VPR Brands (VPRB) Reports First Quarter 2024 Financial Results • VPRB • May 17, 2024 8:04 AM
ILUS Provides a First Quarter Filing Update • ILUS • May 16, 2024 11:26 AM
Cannabix Technologies and Omega Laboratories Inc. enter Strategic Partnership to Commercialize Marijuana Breathalyzer Technology • BLO • May 16, 2024 8:13 AM
Avant Technologies to Revolutionize Data Center Management with Proprietary AI Software Platform • AVAI • May 16, 2024 8:00 AM